Advice

following an abbreviated submission:

filgotinib (Jyseleca®) is accepted for use within NHSScotland.

Indication under review: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Filgotinib provides an additional treatment choice in the therapeutic class of janus kinase (JAK) inhibitors.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Download detailed advice634KB (PDF)

Download

Medicine details

Medicine name:
filgotinib (Jyseleca)
SMC ID:
SMC2467
Indication:

For treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Pharmaceutical company
Galapagos Biotech Ltd
BNF chapter
Gastro-intestinal system
Submission type
Abbreviated
Status
Accepted
Date advice published
09 May 2022